Metastatic melanoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Undifferentiated carcinoma of ovary
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Because little is known about CD44 in human hepatocellular carcinoma (HCC), we investigated its expression in tissue specimens from primary lesions (12 cases), in smear specimens from peritoneal effusions (2 cases), and in cell lines (HCC cell lines, KIM-1, KYN-1, KYN-2, KYN-3, HAK-1A, and HAK-1B; combined hepatocholangiocarcinoma cell lines, KMCH-1 and KMCH-2; and bile duct carcinoma cell lines, KMC-1 and KMBC).
|
7537711 |
1995 |
Combined Hepatocellular Carcinoma and Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Because little is known about CD44 in human hepatocellular carcinoma (HCC), we investigated its expression in tissue specimens from primary lesions (12 cases), in smear specimens from peritoneal effusions (2 cases), and in cell lines (HCC cell lines, KIM-1, KYN-1, KYN-2, KYN-3, HAK-1A, and HAK-1B; combined hepatocholangiocarcinoma cell lines, KMCH-1 and KMCH-2; and bile duct carcinoma cell lines, KMC-1 and KMBC).
|
7537711 |
1995 |
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Furthermore, we predict that a clonal, morphologically less differentiated subpopulation such as HAK-1B is more aggressive in proliferation and may be closely related to subsequent tumor progression in hepatocellular carcinoma.
|
8393423 |
1993 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Morphologically, HAK-1A and 1B resembled well-differentiated hepatocellular carcinoma cells in the outer layer of the original tumor and poorly differentiated ones in the inner layer, respectively.
|
8393423 |
1993 |
Nodule
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
We established two distinct human hepatocellular carcinoma cell lines (HAK-1A and 1B) from a single nodule showing a three-layered structure with a different histological grade in each layer.
|
8393423 |
1993 |
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, we predict that a clonal, morphologically less differentiated subpopulation such as HAK-1B is more aggressive in proliferation and may be closely related to subsequent tumor progression in hepatocellular carcinoma.
|
8393423 |
1993 |
Well Differentiated Hepatocellular Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Morphologically, HAK-1A and 1B resembled well-differentiated hepatocellular carcinoma cells in the outer layer of the original tumor and poorly differentiated ones in the inner layer, respectively.
|
8393423 |
1993 |
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
These findings suggest that HAK-2 is a new human HCC cell line representing two morphological characteristics; (1) formation of various structures in the presence of extracellular matrix and (2) frequent spontaneous apoptosis in vitro.
|
9436038 |
1997 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
HAK-3 would be useful in studies on the acceleration mechanisms of cancer cell proliferation by growth factors and of chemotaxis by dHGF.
|
10493947 |
1999 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
HAK-3 would be useful in studies on the acceleration mechanisms of cancer cell proliferation by growth factors and of chemotaxis by dHGF.
|
10493947 |
1999 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
HAK-1B/Cap43 also showed decreased tumor growth rates as compared with its control counterpart in vivo.
|
21775055 |
2011 |
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The functional role of the TCF-4 isoforms was evaluated in OUMS-29 (an immortalized hepatocyte-derived) and HAK-1A (a well-differentiated HCC) cell lines using stable clones overexpressing the TCF-4 isoforms.
|
23648141 |
2013 |
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
In a nude mice xenograft model, the HAK-1A-derived TCF-4C clone rapidly developed tumours compared with the TCF-4D clone.
|
23648141 |
2013 |
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.
|
23929716 |
2013 |
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Gene expression and bioinformatic analyses of NSCLC cells with ablated miRNA-214, identified a number of metastasis-related target genes, including pregnancy-associated plasma protein A (PAPP-A), alpha protein kinase 2 (ALPK2), cyclin-dependent kinase 6 (CDK6) and tumor necrosis-factor alpha-induced protein 3 (TNFAIP3).
|
23929716 |
2013 |
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We used a well-differentiated HCC cell line (HAK-1A) and a poorly differentiated HCC cell line (HAK-1B) established from a single nodule with histological heterogeneity.
|
24325739 |
2014 |
Nodule
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
We used a well-differentiated HCC cell line (HAK-1A) and a poorly differentiated HCC cell line (HAK-1B) established from a single nodule with histological heterogeneity.
|
24325739 |
2014 |
Anaplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
HAK-1B arose because of clonal dedifferentiation of HAK-1A.
|
24325739 |
2014 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Alpha-kinase 2 (ALPK2), suggested to be a novel tumour-suppressor gene down-regulated by oncogenic KRAS, plays a pivotal role in luminal apoptosis in normal colonic crypts.
|
28668886 |
2017 |
Malignant Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
We identified that one of the ALPK2 germline variants, rs55674018 (rs55674018" genes_norm="115701">p.Q1853E), was significantly associated with the presence of cancer (adjusted odds ratio(OR)=4.39; 95% confidence interval(CI)=1.31-14.78, p=0.001).
|
28668886 |
2017 |
Primary malignant neoplasm
|
0.020 |
GeneticVariation
|
group |
BEFREE |
We identified that one of the ALPK2 germline variants, rs55674018 (rs55674018" genes_norm="115701">p.Q1853E), was significantly associated with the presence of cancer (adjusted odds ratio(OR)=4.39; 95% confidence interval(CI)=1.31-14.78, p=0.001).
|
28668886 |
2017 |
Colorectal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine the association between ALPK2 germline variants and colorectal cancer.
|
28668886 |
2017 |
Malignant neoplasm of colon and/or rectum
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine the association between ALPK2 germline variants and colorectal cancer.
|
28668886 |
2017 |